More Articles

Boehringer Ingelheim starts biosimilar rituximab trial Biosimilars/Research | Posted 21/09/2012

Germany-based Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) is starting a Phase III trial for a biosimilar version of rituximab.

Canada takes another step towards generics Generics/General | Posted 21/09/2012

For the first time, two of Canada’s biggest health insurance companies are going to require that generics be prescribed if one is available.

Fresenius cashes in on drug shortages Pharma News | Posted 21/09/2012

German healthcare conglomerate Fresenius has posted substantial growth across all regions and product areas during the first half of 2012 for its US business Fresenius Kabi. The growth has been lar...

Hospira acquires manufacturing, R & D facilities in India Generics/News | Posted 21/09/2012

On 29 August 2012, US-based Hospira announced an agreement to acquire an API (active pharmaceutical ingredient) manufacturing facility, together with an associated research and development (R &...

Sun recalls biosimilar brain treatment Biosimilars/News | Posted 21/09/2012

India-based Sun Pharmaceutical Industries (Sun Pharma) is once again in the news, but for the wrong reasons.

Biosimilar comparability debate continues Biosimilars/Research | Posted 14/09/2012

Authors Schellekens and Moors comment on the response from EMA’s Biosimilar Medicinal Products Working Party to questions that they raised regarding EMA’s comprehensive biosimilar regulatory pathwa...

Teva receives FDA approval for filgrastim in the US Biosimilars/News | Posted 14/09/2012

Teva Pharmaceutical Industries (Teva) announced on 30 August 2012 that FDA had granted approval for tbo-filgrastim (XM02 filgrastim), the first new granulocyte colony-stimulating factor (G-CSF) to...

2020 outlook for biosimilars: opportunities and hurdles Reports | Posted 14/09/2012

Many different factors will influence the future growth of the biosimilars market in different world regions, both in terms of access to biosimilars and uptake. Producers will need to re-evaluate t...